Amphastar’s Forteo ANDA Hit With CRL As Wait Goes On
Forteo Has No Tangible Patent Protection But Complexity A Major Hurdle
Amphastar will not be receiving approval in 2022 for its proposed generic version of Eli Lilly’s Forteo (teriparatide) peptide for the treatment of osteoporosis, after the FDA told the company it could not issue an approval at this stage.
